Literature DB >> 25512635

Melanoma BRAF fusions--letter.

Thomas Botton1, Iwei Yeh1, Boris C Bastian2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25512635      PMCID： PMC4270079          DOI： 10.1158/1078-0432.CCR-14-0058

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  4 in total

1.  Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?

Authors:  Thierry Passeron; Jean-Philippe Lacour; Maryline Allegra; Coralie Ségalen; Anne Deville; Antoine Thyss; Damien Giacchero; Jean-Paul Ortonne; Corine Bertolotto; Robert Ballotti; Philippe Bahadoran
Journal:  Exp Dermatol       Date:  2011-12       Impact factor: 3.960

2.  Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.

Authors:  Thomas Botton; Iwei Yeh; Tyrrell Nelson; Swapna S Vemula; Alyssa Sparatta; Maria C Garrido; Maryline Allegra; Stephane Rocchi; Philippe Bahadoran; Timothy H McCalmont; Philip E LeBoit; Elizabeth A Burton; Gideon Bollag; Robert Ballotti; Boris C Bastian
Journal:  Pigment Cell Melanoma Res       Date:  2013-08-19       Impact factor: 4.693

3.  BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.

Authors:  Katherine E Hutchinson; Doron Lipson; Philip J Stephens; Geoff Otto; Brian D Lehmann; Pamela L Lyle; Cindy L Vnencak-Jones; Jeffrey S Ross; Jennifer A Pietenpol; Jeffrey A Sosman; Igor Puzanov; Vincent A Miller; William Pao
Journal:  Clin Cancer Res       Date:  2013-12-15       Impact factor: 12.531

4.  Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.

Authors:  Vivek Subbiah; Shannon N Westin; Kai Wang; Dejka Araujo; Wei-Lien Wang; Vincent A Miller; Jeffrey S Ross; Phillip J Stephens; Gary A Palmer; Siraj M Ali
Journal:  J Hematol Oncol       Date:  2014-01-14       Impact factor: 17.388
  4 in total
  2 in total

1.  Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation.

Authors:  Klaus J Busam; Ricardo E Vilain; Trina Lum; Jonathan A Busam; Travis J Hollmann; Robyn P M Saw; Daniel C Coit; Richard A Scolyer; Thomas Wiesner
Journal:  Am J Surg Pathol       Date:  2016-06       Impact factor: 6.394

2.  Primary and Metastatic Melanoma With NTRK Fusions.

Authors:  Cecilia Lezcano; Alexander N Shoushtari; Charlotte Ariyan; Travis J Hollmann; Klaus J Busam
Journal:  Am J Surg Pathol       Date:  2018-08       Impact factor: 6.394
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.